Managed by Brandon Capital, Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries originating from member research organisations, providing both capital and expertise to guide the successful development of new therapies.
Brandon BioCatalyst is a unique collaboration of investors, CSL, government and more than 50 leading medical research institutes and hospitals united by a single purpose: generating cutting edge, next generation medical therapies and technologies to improve health and save lives.
50+ Medical research institutes and hospitals
ACT Government
NSW Government Health
Government of South Australia
Queensland Government
Victorian Government
Western Australian Government
Ministry of Business, Innovation & Employment (MBIE) NZ
Brandon Capital
Australian Government
Australian Super
Hesta
Host Plus
TelstraSuper
CSL
SVI is an independent medical research institute that conducts research into the cause, prevention and treatment of diseases that are common and have serious effects on health. We strive, through our research, to help alleviate the enormous financial, emotional and physical impacts of these diseases on individuals, their families and the community.
ViewMater Research is a recognised leader in medical research. Our bench to bedside philosophy sees us working across Mater Health’s hospitals and health services, The University of Queensland, and the world-class Translational Research Institute (TRI).
ViewThe George Institute for Global Health is a not-for-profit global medical research institute established and headquartered in Sydney, with major centres in China, India and the UK, and an international network of experts and collaborators.
View
Brandon Capital manages Brandon BioCatalyst, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies.
Brandon Capital website
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.
